Fundraising FoxQuark Venture Inc. — Full Portfolio
5 tracked investments · listed companies and verified rows first
Microbion develops therapeutics targeting biofilm-associated infections, with a lead candidate (Pravibismane) in clinical development for diabetic foot ulcer, orthopedic implant, and respiratory infections.
BiotechHealthtechMedical DevicesBozeman, US
Karim Lalji(Executive Officer, Director)inFrank Kerins(Executive Officer)Brett Baker(Founder, President & Chief Innovation Officer)
BoardRodger May(Director)Jared Carney(Director)Steven Schellong(Director)
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.
AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US
Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in
Co-investors20/20 HealthCare Partners LLCBosch VenturesNew Era Capital PartnersOrbiMedPeregrine VenturesPitango+2 more
Canary Medical develops implantable orthopedic medical devices, including smart sensors and digital health solutions, for knee replacement and other surgical applications.
Digital HealthIoTMedical DevicesNew York, US
Bill Hunter(Founding Member, CEO and CMO)inFred Cushner(Founding Member and Chief Surgical Officer)Jeff Gross(Founding Member and Chief Technology Officer)
Co-investorsRelentless Pursuit PartnersHorizon Technology FinanceRosetta Capital Ltd.
BiotechWatertown, US
Robert S. Langer, Sc.D.(Director)Armon Sharei, Ph.D.(Executive Officer, Director)Armon Sharei(Executive Officer, Director)Amy W. Schulman(Executive Officer, Director)Kris Elverum(Executive Officer)Howard Bernstein(Executive Officer)
Co-investorsAlumni Ventures+ND CapitalGV (Google Ventures)Illumina VenturesInvusJDRF T1D Fund+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.